Biogazelle is a development stage biotechnology company deploying the power of RNA as source of next generation diagnostics and therapeutics.
The proprietary biomarker discovery platform covers the entire workflow from study design, data generation to identification of RNA biomarkers. State-of-the-art RNA sequencing methods are used to profile the entire transcriptome (+80,000 candidate biomarkers) on clinically relevant samples (including fixed tissues and body fluids). Advanced data mining methods are applied to identify robust biomarker signatures, that can be developed into a PCR-based molecular diagnostic test.
Biogazelle’s platform is driving its own RNA biomarker discovery programs and accelerates that of its customers and partners.
Besides RNA biomarker discovery and diagnostics, Biogazelle is also active in the development of RNA targeting anti-cancer therapies, based on the silencing of specific long non-coding RNAs. The running programs focus on colon, liver and lung cancer. We welcome co-development opportunities.